Our approach is guided by the specific needs
of each patient condition
ATSENA THERAPEUTICS’ platform is powered by adeno-associated virus (AAV) vectors engineered to overcome the unique hurdles presented by inherited retinal disease. The approach is guided by the specific needs of each patient condition. Our novel AAV gene therapy constructs are customized for ocular gene therapies. We utilize an AAV capsid, payload and delivery approach that is engineered for each disease, including dual vectors constructed to deliver larger genetic payloads for genetic mutations that have been untreatable with a single AAV vector.
Dual AAV vector approach for the delivery of MYO7A gene therapy